BioPharma Dive March 24, 2025
Sponsored content By Intelligencia AI
Developing a new cancer treatment is a high-stakes endeavor where every decision can make or break success. Pharmaceutical companies must balance speed, risk and regulatory hurdles while ensuring patients have access to life-saving treatments as soon as possible. Based on Intelligencia AI’s comprehensive, proprietary database of over 20,000 industry-sponsored, interventional oncology clinical programs (around 12,400 clinical trials), recent insights highlight key strategies that can streamline the clinical development process and improve the chances of regulatory approval.
We analyzed each strategy based on its impact on time to market and historical success rates. The key findings are illustrated in the figure below, with a detailed breakdown of each strategy in the following sections, and you can...
Today's Sponsors
Today's Sponsor